M M Regan1, E K O'Donnell2, W K Kelly3, S Halabi4, W Berry5, S Urakami6, N Kikuno6, W K Oh7. 1. Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA. Electronic address: mregan@jimmy.harvard.edu. 2. Beth Israel Deaconess Medical Center, Boston, MA. 3. Department of Medicine and Surgery, Yale University, New Haven, CT. 4. Department of Biostatistics and Bioinformatics, Duke University Medical Center, Durham, NC. 5. US Oncology, Inc., Houston, TX; Cancer Centers of North Carolina, Cary, NC, USA. 6. Department of Urology, Shimane University School of Medicine, Izumo, Japan. 7. Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Abstract
BACKGROUND: Docetaxel is associated with prolonged survival in castration-resistant prostate cancer (CRPC). Platinum compounds have modest but distinct single-agent activity. Carboplatin may have greatest potential for benefit when combined with taxanes. We investigated whether there is a subset of patients with CRPC for whom the efficacy of combination taxane-estramustine-carboplatin (TEC) chemotherapy may be greatest. PATIENTS AND METHODS: Individual patient data (n = 310) were obtained from seven trials using TEC chemotherapy. Prostate-specific antigen (PSA) response was defined as > or = 50% post-therapy decline from baseline. Overall survival was defined from baseline to death from any cause. Logistic and Cox regression were used to investigate heterogeneity in outcome to TEC by patient and disease characteristics. Predicted survival probabilities were calculated from the Halabi Cancer and Leukemia Group B (CALGB) nomogram. RESULTS: The pooled PSA response proportion was 69% [95% confidence interval (CI) 56% to 80%]. There was no evidence of differential PSA response by disease characteristics. Established prognostic factors were associated with survival. The pooled 12-month survival estimate of 79% (95% CI 71% to 84%) was higher than the median 59% 12-month nomogram-predicted survival. CONCLUSIONS: TEC chemotherapy has significant clinical activity in CRPC. A randomized, controlled trial evaluating the addition of carboplatin to taxane-based chemotherapy is needed to elucidate the value of carboplatin in CRPC.
BACKGROUND:Docetaxel is associated with prolonged survival in castration-resistant prostate cancer (CRPC). Platinum compounds have modest but distinct single-agent activity. Carboplatin may have greatest potential for benefit when combined with taxanes. We investigated whether there is a subset of patients with CRPC for whom the efficacy of combination taxane-estramustine-carboplatin (TEC) chemotherapy may be greatest. PATIENTS AND METHODS: Individual patient data (n = 310) were obtained from seven trials using TEC chemotherapy. Prostate-specific antigen (PSA) response was defined as > or = 50% post-therapy decline from baseline. Overall survival was defined from baseline to death from any cause. Logistic and Cox regression were used to investigate heterogeneity in outcome to TEC by patient and disease characteristics. Predicted survival probabilities were calculated from the Halabi Cancer and Leukemia Group B (CALGB) nomogram. RESULTS: The pooled PSA response proportion was 69% [95% confidence interval (CI) 56% to 80%]. There was no evidence of differential PSA response by disease characteristics. Established prognostic factors were associated with survival. The pooled 12-month survival estimate of 79% (95% CI 71% to 84%) was higher than the median 59% 12-month nomogram-predicted survival. CONCLUSIONS:TEC chemotherapy has significant clinical activity in CRPC. A randomized, controlled trial evaluating the addition of carboplatin to taxane-based chemotherapy is needed to elucidate the value of carboplatin in CRPC.
Authors: William Berry; David Friedland; John Fleagle; Don Jackson; Des Ilegbodu; Kristi A Boehm; Lina Asmar Journal: Clin Genitourin Cancer Date: 2006-09 Impact factor: 2.872
Authors: William K Oh; Elizabeth Hagmann; Judith Manola; Daniel J George; Timothy D Gilligan; Joseph O Jacobson; Matthew R Smith; Donald S Kaufman; Philip W Kantoff Journal: Clin Cancer Res Date: 2005-01-01 Impact factor: 12.531
Authors: Gunnar Steineck; Victor Reuter; William K Kelly; Richard Frank; Larry Schwartz; Howard I Scher Journal: Acta Oncol Date: 2002 Impact factor: 4.089
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Ahmedin Jemal; Taylor Murray; Alicia Samuels; Asma Ghafoor; Elizabeth Ward; Michael J Thun Journal: CA Cancer J Clin Date: 2003 Jan-Feb Impact factor: 508.702
Authors: David B Solit; Michael Morris; Susan Slovin; Tracy Curley; Lawrence Schwartz; Steven Larson; Michael W Kattan; Beryl Hartley-Asp; Howard I Scher; W Kevin Kelly Journal: Cancer Date: 2003-11-01 Impact factor: 6.860
Authors: Paul G Corn; Elisabeth I Heath; Amado Zurita; Naveen Ramesh; Lianchun Xiao; Emi Sei; Elsa Li-Ning-Tapia; Shi-Ming Tu; Sumit K Subudhi; Jennifer Wang; Xuemei Wang; Eleni Efstathiou; Timothy C Thompson; Patricia Troncoso; Nicholas Navin; Christopher J Logothetis; Ana M Aparicio Journal: Lancet Oncol Date: 2019-09-09 Impact factor: 41.316
Authors: Christoph W M Reuter; Michael A Morgan; Philipp Ivanyi; Martin Fenner; Arnold Ganser; Viktor Grünwald Journal: World J Urol Date: 2010-03-14 Impact factor: 4.226
Authors: Mark M Pomerantz; Sandor Spisák; Li Jia; Angel M Cronin; Istvan Csabai; Elisa Ledet; A Oliver Sartor; Irene Rainville; Edward P O'Connor; Zachary T Herbert; Zoltan Szállási; William K Oh; Philip W Kantoff; Judy E Garber; Deborah Schrag; Adam S Kibel; Matthew L Freedman Journal: Cancer Date: 2017-06-13 Impact factor: 6.860
Authors: Jose Mauricio Mota; Ethan Barnett; Jones T Nauseef; Bastien Nguyen; Konrad H Stopsack; Andreas Wibmer; Jessica R Flynn; Glenn Heller; Daniel C Danila; Dana Rathkopf; Susan Slovin; Philip W Kantoff; Howard I Scher; Michael J Morris; Nikolaus Schultz; David B Solit; Wassim Abida Journal: JCO Precis Oncol Date: 2020-04-16